General Biologicals Corporation announced on the 2nd that it has signed a three-year exclusive distribution agreement with a distributor in Brazil. The main products to be sold include ELISA serum antibody assays, A/B/C/D hepatitis detection assays, as well as CLIA chemiluminescence immunoassay and molecular diagnostic PCR equipment and related products. The Brazilian distributor has already partnered with over 40% of blood donation centers locally and has accumulated over 200 laboratories and hospital sales channels. Deliveries are expected to gradually commence from April onwards, driving the new wave of growth momentum for GBC.
GBC stated that the revenue contribution from Taiwan, the Middle East, and Southeast Asia accounted for 42%, 13%, and 2%, respectively, in the first two months of this year. In addition to existing sales records in Mexico in the South American region, the collaboration with the Brazilian distributor will help create sales momentum for GBC's precision testing equipment and reagents, enhancing the group's sales footprint in South America and further expanding its overall overseas sales territory.
Benefiting from the group's integrated operation model encompassing research and development, manufacturing, clinical trials, and global distribution networks, as well as the planned establishment of the GBC AI Park headquarters in the Zhubei AI Smart Park with energy-saving and carbon reduction features, along with nine major centers, slated for completion and operation in the second half of 2024, GBC aims to expand its operational scale in precision testing and liquid biopsy businesses. This is expected to complement the existing resources of the Zhubei factory located in the Hsinchu Science Park and optimize its layout in the broader health field, thereby facilitating GBC's international market development opportunities.
Looking ahead, GBC is optimistic about the continued increase in market demand for precision medical testing and liquid biopsy. It is actively enhancing its five core business areas, namely precision testing, liquid biopsy, CDMO (Contract Development and Manufacturing Organization), testing services, and P113 antimicrobial peptide drugs. Moreover, by participating in important international biotech and medical exhibitions, GBC aims to increase the visibility of the GBC brand in the market, promote the uptake of precision testing, liquid biopsy, and other business orders, expand cooperation opportunities with overseas distributors, and create robust growth momentum for GBC's future operations.
Resource (Mandarin):
